FGFR3-TACC3 fusions were detected in one glioblastoma patient, two urothelial carcinoma patients, and one patient with adrenal carcinoma who showed partial response under treatment with erdafitinib [98]. This evidence concerns the gene FGFR3 and urothelial carcinoma.